scale up pitfalls [Study Per­for­mance]

posted by Dr_Dan  – 2016-10-26 15:11 (1549 d 14:11 ago) – Posting: # 16754
Views: 2,026

Dear all
Provided that a lab scale batch of a generic formulation demonstrated bioequivalence to the RLD how big would be the risk of commercial scale batch to fail?
IMHO factors affecting the formulation after method transfer to the CMO are different manufacturing equipment and different total amounts of drug and excipients. If the formulation and the manufacturing process remains the same and all characteristics and specification of critical quality attributes of the drug product, such as dissolution are met wouldn't it be reasonable to assume bioequivalence for the commercial scale batch? Do you have any experience with failed upscaling?
CPMP/EWP/QWP/1401/98 Rev. 1/ Corr ** states for oral solid forms for systemic action that "the test product should usually originate from a batch of at least 1/10 of production scale or 100,000 units, whichever is greater, unless otherwise justified." Considering this upscaling shouldn´t really be a problem, right?
Looking forward to your reply

Kind regards and have a nice day
Dr_Dan

Complete thread:

Activity
 Admin contact
21,310 posts in 4,445 threads, 1,489 registered users;
online 41 (0 registered, 41 guests [including 25 identified bots]).
Forum time: Saturday 05:22 UTC (Europe/Vienna)

Any sufficiently advanced technology
is indistinguishable from magic.    Arthur C. Clarke

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5